Tumor Biology

, Volume 37, Issue 12, pp 16141–16149 | Cite as

Effects and mechanisms of action of SARI on androgen-independent prostate cancer (DU145) cells

Original Article
  • 104 Downloads

Abstract

This study aimed to characterize the role and mechanisms of action of suppressor of AP-1, regulated by IFN (SARI) in androgen-independent prostate cancer cells using the DU145 cell line. Prostate cancer cell lines were transfected to permit both the overexpression and inhibition of SARI. MTT assays and Transwell assays were performed to detect the effects of SARI overexpression and inhibition on the proliferation activity, invasiveness, and metastatic ability of DU145 cells. Expression of vascular endothelial growth factor (VEGF) and tyrosine-phosphorylated signal transducer and activator of transcription 3 (p-STAT3) was monitored in the experimental groups using a qPCR assay and western blot analysis. Additionally, DU145 cells were separately treated with 5, 50, and 100 μmol/L AG490 for 48 h and SARI expression was detected using the qPCR assay and western blot analysis. We also monitored the effects of AG490 treatment (100 μmol/L for 48 h) on both the SARI-SiRNA DU145 cells and empty vector DU145 (DU145-V) cells using the MTT assay and a Transwell migration assay. SARI overexpression and SARI-SiRNA DU145 prostate cancer cell lines were successfully established. The proliferation activity and the invasion and migration abilities of DU145-SARI cells were significantly lower compared with the DU145-V group (P < 0.05). Conversely, the proliferation activity and the invasion and migration abilities of SARI-SiRNA cells were significantly higher compared with the DU145-V group (P < 0.05). VEGF and p-STAT3 expression levels were lower in the SARI overexpression group compared with the DU145-V group and the control group (P < 0.05). In contrast, VEGF and p-STAT3 expression levels were higher in the SARI-SiRNA group compared with both the DU145-V group and the control group (P < 0.05). In comparison with the control group, SARI expression levels were higher in DU145 cells treated with 50 and 100 μmol/L AG490. Upon treatment with 100 μmol/L AG490 for 48 h, the proliferation activity and invasiveness and migration abilities of SARI-SiRNA cells were significantly higher compared with the DU145-V group (P < 0.05). SARI significantly affects the proliferation, invasion, and metastasis of DU145 cells. It is possible that SARI inhibits the proliferation, invasion, and migration of androgen-independent prostate cancer cells by regulating downstream genes through the SARI/STAT3/VEGF pathways.

Keywords

Sari P-STAT3 VEGF Prostate cancer AG490 

Notes

Compliance with ethical standards

Conflicts of interest

None.

References

  1. 1.
    Jennifer C, Sally E, Stephen A, et al. The burden of prostate cancer in Asian nations.Journal of. Carcinogenesis. 2012;11(7):61–9.Google Scholar
  2. 2.
    Chen W, Zheng R, Zeng H, et al. The updated incidences and mortalities of major cancers in China, 2011. Chin J Cancer. 2015:11–53.Google Scholar
  3. 3.
    Rebecca L, Siegel KD, Miller A, Jemal DVM. Cancer statistics, 2016. CA. Cancer J Clin. 2016;66:7–30.CrossRefGoogle Scholar
  4. 4.
    Su ZZ, Lee SG, Emdad L, et al. Cloning and characterization of SARI (suppressor of AP-1, regulated by IFN). Proc Natl Acad Sci USA. 2008;105(52):20906–11.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Zhou RJ, Shi Z, et al. Decreased SARI expression predicts poor prognosis of Chinese patients with non-small cell lung cancer. Int J Clin Exp Pathol. 2013;6(10):2056–63.PubMedPubMedCentralGoogle Scholar
  6. 6.
    Ma H, Liang X, Chen Y, et al. Decreased expression of BATF2 is associated with a poor prognosis in hepatocellular carcinoma. Int J Cancer. 2011;128(4):771–7.CrossRefPubMedGoogle Scholar
  7. 7.
    Wen H, Chen Y, Hu Z, et al. Decreased expression of BATF2 is significantly associated with poor prognosis in oral tongue squamous cell carcinoma. Oncol Rep. 2014;31(1):169–74.PubMedGoogle Scholar
  8. 8.
    Qian C, Yonghong G, Binghui L. Expression and mechanism of action of the SARI tumor suppressor in prostate cancer. Int J Clin Exp Pathol. 2015;8(7):7953–60.Google Scholar
  9. 9.
    Bromberg JF, Wrzeszezynska MH, Devgan G, et al. Stat3 as an oncogene. Cell. 1999;98(3):295–303.CrossRefPubMedGoogle Scholar
  10. 10.
    Folkman J, Klagsbrun M. Angiogenic factors. Science. 1987;235:442–7.CrossRefPubMedGoogle Scholar
  11. 11.
    Weidner N, Semple JP, Welch W, et al. Tumor angiogenesis and metastasis. Correlation in invasive breast carcinoma. N Engl J Med. 1991;324:1–8.CrossRefPubMedGoogle Scholar
  12. 12.
    Wang C, Su Y, Zhang L, et al. The function of SARI in modulating epithelial-mesenchymal transition and lung adenocarcinoma metastasis. PLoS One. 2012;7(9).Google Scholar
  13. 13.
    Dash R, Bhoopathi P, Das SK, et al. Novel mechanism of MDA-7/IL-24 cancer-specific apoptosis through SARI induction. Cancer Res. 2014;15;74(2):563–74.CrossRefGoogle Scholar
  14. 14.
    Zheng SD, Wu S, Gui JH, et al. Research on the effects of BATF2 of Wnt signaling pathway. Chinese. J Cell Biol. 2012;34(4):343–8.Google Scholar
  15. 15.
    Dash R, ZZ S, Lee SG, et al. Inhibition of AP-1 by SARI negatively regulates transformation progression mediated by CCN1. Oncogene. 2010;29(31):4412–23.CrossRefPubMedGoogle Scholar
  16. 16.
    Zhang Y-x, Yan L, Liu G-y, et al. Inhibition of janus kinase 2 by compound AG490 suppresses the proliferation of MDA-MB-231 cells via up-regulating SARI (suppressor of AP-1, regulated by IFN). Iran J Basic Med Sci. 2015;18(6):599–603.PubMedPubMedCentralGoogle Scholar
  17. 17.
    Sun J, Yu M, Lu Y, et al. Carcinogenic metalloid arsenic induces expression of indig oncogene through JNK and STAT3 activation. Cancer Leu. 2014;346(2):257–63.CrossRefGoogle Scholar
  18. 18.
    Ni Z, Lou W, Eddy S, Leman G, et al. Inhibition of constitutively activated Stat3 signaling pathway suppresses growth of prostate cancer cells. Cancer Res. 2000;60:1225–8.PubMedGoogle Scholar
  19. 19.
    Nielsen M1, Kaltoft K, Nordahl M, et al. Constitutive activation of a slowly migrating isoform of Stat3 in mycosis fungoides: tyrphostin AG490 inhibits Stat3 activation and growth of mycosis fungoides tumor cell lines. Proc Natl Acad Sci USA. 1997;24;94(13):6764–9.CrossRefGoogle Scholar
  20. 20.
    Krol M, Pawłowski KM, Dolka I, et al. Density of Gr1-positive myeloid precursor cells, p-STAT3 expression and gene expression pattern in canine mammary cancer metastasis. Vet Res Commun 2011. 35:409–23.Google Scholar
  21. 21.
    Schroeder A, Herrmann A, Cherryholmes G, et al. Loss of androgen receptor expression promotes a stem-like cell phenotype in prostate cancer through STAT3 signaling. Cancer Res. 2014;74(4):1227–37.CrossRefPubMedGoogle Scholar
  22. 22.
    Sun Y, Guo B-f, Xu L-b, et al. Stat3-siRNA inhibits the growth of gastric cancer in vitro and in vivo. Cell Biochem Funct. 2015;33:495–502.CrossRefPubMedGoogle Scholar
  23. 23.
    Tang YJ, Sun ZL, WG W, et al. Inhibitor of signal transducer and activator of transcription 3 (STAT3) suppresses ovarian cancer growth, migration and invasion and enhances the effect of cisplatin in vitro. Genet Mol Res. 2015;30;14(1):2450–60.CrossRefGoogle Scholar
  24. 24.
    William M. Burke, Xiaohong Jin, Huey-Jen Lin, et al. inhibition of constitutively active Stat3 suppresses growth of human ovarian and breast cancer cells. Oncogene. 2001;20:7925–34.CrossRefGoogle Scholar
  25. 25.
    Tang YJ, Sun ZL, Wu WG, et al. Inhibitor of signal transducer and activator of transcription 3 (STAT3) suppresses ovarian cancer growth, migration and invasion and enhances the effect of cisplatin in vitro. Genet Mol Res. 2015;14(1):2450–60.CrossRefPubMedGoogle Scholar
  26. 26.
    Wei Z, Jiang X, Qiao H, et al. STAT3 interacts with Skp2/p27/p21 pathway to regulate the motility and invasion of gastric cancer cells. Cell Signal. 2013;25(4):931–8.CrossRefPubMedGoogle Scholar
  27. 27.
    Chiba T, Yamada M, Aiso S. Targeting the JAK2 /STAT3 axis in Alzheimer’s disease. Expert Opin Ther Targets. 2009;13(10):1155–67.CrossRefPubMedGoogle Scholar
  28. 28.
    Chan KS, Cabajal S, Kiguchi K, et al. Epidermal growth factor receptor mediated activation of STAT3 during multistage skin carcinogenesis. Cancer Res. 2004;64(7):2382–9.CrossRefPubMedGoogle Scholar
  29. 29.
    Meydan N, Grunberger T, Dadi H, et al. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature. 1996;15;379(6566):645–8.CrossRefGoogle Scholar
  30. 30.
    Huang C, Yang G, Jiang T, et al. Effects of IL-6 and AG490 on regulation of Stat3 signaling pathway and invasion of human pancreatic cancer cells in vitro. J Exp Clin Cancer Res. 2010;29:51.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Huang YH, Zhang, Huang Y, et al. Interferon-α/β inhibits lymphoma cell proliferation by up-regulating SARI expression. J Third Mil Med Univ. 2012;34(24):2465–8.Google Scholar
  32. 32.
    Zhao D, Pan C, Sun J, et al. VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate myc and Sox2. Oncogene. 2015;34:3107–19.CrossRefPubMedGoogle Scholar
  33. 33.
    Wei D, Le X, Zheng L, et al. STAT3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene. 2003;22(3):319–29.CrossRefPubMedGoogle Scholar
  34. 34.
    Zhao M, Gao FH, Wang JY, et al. JAK2/STAT3 signaling pathway activation mediated tumor angiogenesis by upregulation of VEGF and bFGF in non-small-cell lung cancer. Lung Cancer. 2011;73:366–74.Google Scholar
  35. 35.
    Bartoli M, Platt D, Lemtalsi T, et al. VEGF differentially activates STAT3 in microvascular endothelial cells. FASEB J. 2003;17(11):1562–64. doi: 10.1096/fj.02-1084fje.

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2016

Authors and Affiliations

  • Qian Chen
    • 1
  • Yonghong Gu
    • 1
  • Shengwang Zhang
    • 2
  • Hao Deng
    • 3
  1. 1.Department of Pathology, The Third Xiangya HospitalThe Central South UniversityChangshaChina
  2. 2.Department of radiology, The Third Xiangya HospitalThe Central South UniversityChangshaChina
  3. 3.Center for Experimental Medicine, The Third Xiangya HospitalThe Central South UniversityChangshaChina

Personalised recommendations